Fate Therapeutics Income Statement (2012-2025) | FATE

1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
11.14M13.41M14.22M17.07M18.41M18.55M14.98M44.36M58.98M0.93M1.94M1.68M1.93M6.77M3.07M1.86M1.63M1.91M1.74M1.37M
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)
44.85M48.02M53.13M69.52M72.14M81.31M79.82M87.19M65.63M40.88M34.27M31.82M32.14M34.60M34.65M33.61M29.14M27.43M25.84M25.43M
Selling, General & Administrative (Quarter)
12.50M12.17M15.72M16.94M20.74M20.35M21.55M21.58M21.94M22.62M18.95M17.93M20.86M17.25M20.80M15.26M13.77M11.45M10.64M10.66M
Restructuring Costs (Quarter)
2.00M
Other Operating Expenses (Quarter)
-2.00M14.74M
Operating Expenses (Quarter)
57.35M60.19M68.85M86.45M92.88M101.66M101.37M108.78M87.57M63.50M53.22M49.75M52.99M51.85M55.45M63.61M42.91M38.88M36.48M36.09M
Operating Income (Quarter)
-46.21M-46.78M-54.62M-69.38M-74.47M-83.11M-86.39M-64.42M-28.59M-62.56M-51.28M-48.08M-51.07M-45.08M-52.38M-61.75M-41.28M-36.97M-34.73M-34.72M
EBIT (Quarter)
-46.21M-46.78M-54.62M-69.38M-74.47M-83.11M-86.39M-64.42M-28.59M-62.56M-51.28M-48.08M-51.07M-45.08M-52.38M-61.75M-41.28M-36.97M-34.73M-34.72M
Non-operating items
Interest & Investment Income (Quarter)
0.38M0.35M0.29M0.30M0.42M0.76M1.79M2.88M3.69M4.38M4.70M4.41M4.15M4.83M4.44M3.87M3.34M2.92M2.58M2.22M
Other Non Operating Income (Quarter)
1.12M4.84M7.00M2.83M8.06M4.30M9.81M0.36M0.18M0.31M0.27M0.27M-8.51M0.04M0.05M2.48M2.35M
Non Operating Income (Quarter)
1.12M-8.35M11.31M0.76M8.78M7.00M2.83M8.06M9.71M9.81M6.11M3.95M3.06M6.66M4.70M9.60M3.66M2.90M2.48M2.35M
Net income details
EBT (Quarter)
-45.83M-46.43M-54.33M-69.08M-74.05M-82.35M-84.60M-61.54M-24.90M-58.18M-46.58M-43.66M-46.92M-40.26M-47.94M-57.87M-37.94M-34.05M-32.16M-32.50M
Profit After Tax (Quarter)
-45.09M-55.13M-43.30M-68.65M-65.69M-76.11M-83.56M-56.36M-18.88M-52.76M-45.17M-44.12M-48.00M-38.43M-47.68M-52.15M-37.62M-34.07M-32.25M-32.37M
Income from Continuing Operations (Quarter)
-45.83M-46.43M-54.33M-69.08M-74.05M-82.35M-84.60M-61.54M-24.90M-58.18M-46.58M-43.66M-46.92M-40.26M-47.94M-57.87M-37.94M-34.05M-32.16M-32.50M
Consolidated Net Income (Quarter)
-45.83M-46.43M-54.33M-69.08M-74.05M-82.35M-84.60M-61.54M-24.90M-58.18M-46.58M-43.66M-46.92M-40.26M-47.94M-57.87M-37.94M-34.05M-32.16M-32.50M
Income towards Parent Company (Quarter)
-45.83M-46.43M-54.33M-69.08M-74.05M-82.35M-84.60M-61.54M-24.90M-58.18M-46.58M-43.66M-46.92M-40.26M-47.94M-57.87M-37.94M-34.05M-32.16M-32.50M
Net Income towards Common Stockholders (Quarter)
-45.83M-46.43M-54.33M-69.08M-74.05M-82.35M-84.60M-61.54M-24.90M-58.18M-46.58M-43.66M-46.92M-40.26M-47.94M-57.87M-37.94M-34.05M-32.16M-32.50M
Additional items
EPS (Basic) (Quarter)
-0.48-0.58-0.45-0.72-0.68-0.79-0.86-0.58-0.19-0.54-0.46-0.45-0.47-0.33-0.40-0.45-0.32-0.29-0.27-0.27
EPS (Weighted Average and Diluted) (Quarter)
-0.58-0.45-0.72-0.68-0.79-0.86-0.58-0.19-0.54-0.46-0.45-0.47-0.33-0.40-0.45-0.32-0.29-0.27-0.27
Shares Outstanding (Weighted Average) (Quarter)
93.43M93.88M94.40M94.75M96.34M96.52M96.69M96.83M98.05M98.40M98.57M98.41M101.10M117.47M117.77M113.69M118.38M118.45M118.64M118.79M
Shares Outstanding (Diluted Average) (Quarter)
94.33M94.40M94.75M96.34M96.52M96.69M96.83M98.05M98.23M98.34M98.41M101.10M109.29M117.77M113.69M118.38M118.53M118.64M118.79M
EBITDA (Quarter)
-45.42M-54.96M-43.30M-69.31M-67.78M-76.64M-83.44M-54.96M-17.67M-52.70M-45.08M-43.61M-48.21M-38.66M-46.42M-52.72M-37.70M-34.20M-32.16M-32.41M
Interest Expenses (Quarter)
Shares Outstanding (Quarter)
93.89M94.27M95.36M95.73M96.54M96.86M97.11M2.79M98.19M98.52M98.59M98.63M113.80M2.76M2.76M113.93M2.76M114.66M115.34M115.36M